Biotechnology and Pharmaceuticals

August 18, 2022

Buy ($175)

Companies covered: GBS Inc. (NASDAQ:GBS), BriaCell Therapeutics Corp. (NASDAQ:BCTX), BioLineRx Ltd. (NASDAQ:BLRX), Achieve Life Sciences (NASDAQ:ACHV), Pfizer, Inc. (NYSE:PFE), GlaxoSmithKline PLC (NYSE:GSK), Dr. Reddy's Laboratories Ltd (NYSE:RDY), Alpha Cognition Inc. (OTCMKTS:ACOGF), Epizyme, Inc. (NASDAQ:EPZM), Turning Point Therapeutics Inc. (NASDAQ:TPTX), Ipsen ADR (OTCMKTS:IPSEY), Bristol-Myers Squibb Company (NYSE:BMY), Argenx SE (ADR) (NASDAQ:ARGX), IVERIC bio Inc. (NASDAQ:ISEE), Blueprint Medicines Corp. (NASDAQ:BPMC), Intellia Therapeutics Inc. (NASDAQ:NTLA), Verve Therapeutics Inc. (NASDAQ:VERV), Beam Therapeutics Inc. (NASDAQ:BEAM), 2Seventy Bio Inc. (NASDAQ:TSVT), Cogent Biosciences Inc. (NASDAQ:COGT), Gilead Sciences, Inc. (NASDAQ:GILD), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Gain Therapeutics Inc. (NASDAQ:GANX), Astria Therapeutics Inc. (NASDAQ:ATXS), Viracta Therapeutics Inc. (NASDAQ:VIRX), Oncternal Therapeutics, Inc. (NASDAQ:ONCT), United Therapeutics Corporation (NASDAQ:UTHR), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Arcellx Inc. (NASDAQ:ACLX), F-Star Therapeutics Inc. (NASDAQ:FSTX), Seagen Inc. (NASDAQ:SGEN), Merck & Company, Inc. (NYSE:MRK), CRISPR Therapeutics AG (NASDAQ:CRSP), Global Blood Therapeutics (NASDAQ:GBT), Krystal Biotech (NASDAQ:KRYS), bluebird bio, Inc. (NASDAQ:BLUE), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Equillium Inc. (NASDAQ:EQ), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), Adial Pharmaceuticals Inc. (NASDAQ:ADIL), Veru Inc. (NASDAQ:VERU), NLS Pharmaceutics AG (NASDAQ:NLSP), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Atreca Inc. (NASDAQ:BCEL), Dare Bioscience (NASDAQ:DARE), Organon & Co. (NYSE:OGN), Gamida Cell Ltd. (NASDAQ:GMDA), Inhibikase Therapeutics, Inc. (NASDAQ:IKT), Geron Corporation (NASDAQ:GERN)

Medical Devices

June 10, 2022

Buy ($175)

Companies covered: Medtronic, Inc. (NYSE:MDT), Baxter International Inc. (NYSE:BAX), Becton, Dickinson and Company (NYSE:BDX), Stryker Corporation (NYSE:SYK), Avantor Inc. (NYSE:AVTR), Edwards Lifesciences Corporation (NYSE:EW), Intuitive Surgical, Inc. (NASDAQ:ISRG), Illumina, Inc. (NASDAQ:ILMN), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Aethlon Medical Inc. (NASDAQ:AEMD), Biolase, Inc. (NASDAQ:BIOL), Bio-Techne Corp (NASDAQ:TECH), electroCore, Inc. (NASDAQ:ECOR), Implantica AG (STO:IMP-A-SDB), ReShape Lifesciences Inc. (NASDAQ:RSLS), SeaSpine Holdings Corp. (NASDAQ:SPNE), Sensus Healthcare (NASDAQ:SRTS)

Biotechnology and Pharmaceuticals

March 18, 2022

Buy ($175)

Companies covered: SCYNEXIS, Inc. (NASDAQ:SCYX), Cidara Therapeutics Inc. (NASDAQ:CDTX), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ContraFect Corporation (NASDAQ:CFRX), Veru Inc. (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Vaxart (NASDAQ:VXRT), NLS Pharmaceutics AG (NASDAQ:NLSP), Medicenna Therapeutics Corp. (NASDAQ:MDNA), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Dermata Therapeutics Inc. (NASDAQ:DRMA), Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), AstraZeneca PLC (NASDAQ:AZN), Chinook Therapeutics Inc. (NASDAQ:KDNY), Autolus Therapeutics PLC (NASDAQ:AUTL), Blackstone Inc. (NYSE:BX), Amgen Inc. (NASDAQ:AMGN), Dynavax Technologies Corporation (NASDAQ:DVAX), AbbVie Inc. (NYSE:ABBV), Pfizer, Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Theseus Pharmaceuticals Inc. (NASDAQ:THRX), 2Seventy Bio Inc. (NASDAQ:TSVT), bluebird bio, Inc. (NASDAQ:BLUE), Cogent Biosciences Inc. (NASDAQ:COGT), Chimerix, Inc. (NASDAQ:CMRX), Deciphera Pharmaceuticals (NASDAQ:DCPH), Bristol-Myers Squibb Company (NYSE:BMY), iTeos Therapeutics Inc. (NASDAQ:ITOS), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), GlaxoSmithKline PLC (NYSE:GSK), Zogenix, Inc. (NASDAQ:ZGNX), Argenx SE (ADR) (NASDAQ:ARGX), Abivax (OTCMKTS:AAVXF), Angion Biomedica Corp. (NASDAQ:ANGN), Biovaxys Technology Corp. (OTCMKTS:BVAXF), Codex DNA, Inc. (NASDAQ:DNAY), COMPASS Pathways PLC (NASDAQ:CMPS), GeNeuro SA (OTCMKTS:GNRRF), GenSight Biologics SA (OTCMKTS:GSGTF), Jaguar Health Inc. (NASDAQ:JAGX), Vyant Bio Inc. (NASDAQ:VYNT)

Biotechnology and Pharmaceuticals

September 30, 2021

Buy ($175)

Companies covered: Autolus Therapeutics PLC (NASDAQ:AUTL), Chinook Therapeutics Inc. (NASDAQ:KDNY), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Bristol-Myers Squibb Company (NYSE:BMY), Incyte Corporation (NASDAQ:INCY), Zoetis Inc. (NYSE:ZTS), IDEXX Laboratories, Inc. (NASDAQ:IDXX), Covetrus (NASDAQ:CVET), Henry Schein, Inc. (NASDAQ:HSIC), Chewy (NYSE:CHWY), Amazon.com, Inc. (NASDAQ:AMZN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Bausch Health Companies (NYSE:BHC), AbbVie Inc. (NYSE:ABBV), Moderna (NASDAQ:MRNA), BioNTech SE (ADR) (NASDAQ:BNTX), Biogen Inc. (NASDAQ:BIIB), UCB Unsponsored Belgium ADR (OTCMKTS:UCBJY), Landos Biopharma Inc. (NASDAQ:LABP), CohBar Inc. (NASDAQ:CWBR), Omeros Corporation (NASDAQ:OMER), STERIS Corporation (NYSE:STE), Cutera, Inc. (NASDAQ:CUTR), Establishment Labs Holdings Inc. (NASDAQ:ESTA), Glaukos Corp (NYSE:GKOS), Cooper Companies, Inc. (The) (NYSE:COO), SmileDirectClub (NASDAQ:SDC), Vericel Corporation (NASDAQ:VCEL), Baxter International Inc. (NYSE:BAX), Hill-Rom Holdings Inc (NYSE:HRC), Soliton Inc. (NASDAQ:SOLY), EssilorLuxottica SA (OTCMKTS:ESLOF), Pulse BioSciences Inc. (NASDAQ:PLSE), Passage Bio Inc. (NASDAQ:PASG), Taysha Gene Therapies Inc. (NASDAQ:TSHA), Iovance Biotherapeutics Inc. (NASDAQ:IOVA), Homology Medicines Inc. (NASDAQ:FIXX), Regenxbio Inc. (NASDAQ:RGNX), Tenaya Therapeutics Inc. (NASDAQ:TNYA), Astellas Pharma Inc. (OTCMKTS:ALPMF), LogicBio Therapeutics Inc. (NASDAQ:LOGC), Intellia Therapeutics Inc. (NASDAQ:NTLA), Pfizer, Inc. (NYSE:PFE), Allogene Therapeutics (NASDAQ:ALLO), Cellectis S.A. (NASDAQ:CLLS), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Rocket Pharmaceuticals (NASDAQ:RCKT), Krystal Biotech (NASDAQ:KRYS), uniQure N.V. (NASDAQ:QURE), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), GBS Inc. (NASDAQ:GBS), Inhibikase Therapeutics, Inc. (NASDAQ:IKT), Mesoblast Limited (NASDAQ:MESO), USA Equities Corp. (OTCMKTS:USAQ)

Medical Devices

June 10, 2021

Buy ($175)

Companies covered: Danaher Corporation (NYSE:DHR), Avantor Inc. (NYSE:AVTR), Agilent Technologies, Inc. (NYSE:A), EXACT Sciences Corporation (NASDAQ:EXAS), PerkinElmer, Inc. (NYSE:PKI), Thermo Fisher Scientific Inc (NYSE:TMO), Abbott Laboratories (NYSE:ABT), Hologic, Inc. (NASDAQ:HOLX), Novocure Ltd. (NASDAQ:NVCR), Illumina, Inc. (NASDAQ:ILMN), Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Edwards Lifesciences Corporation (NYSE:EW), Quidel Corporation (NASDAQ:QDEL), Intuitive Surgical, Inc. (NASDAQ:ISRG), Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX), PPD Inc. (NASDAQ:PPD), DexCom, Inc. (NASDAQ:DXCM), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Stryker Corporation (NYSE:SYK), Glaukos Corp (NYSE:GKOS), Cooper Companies, Inc. (The) (NYSE:COO), Insulet Corporation (NASDAQ:PODD), Inogen, Inc (NASDAQ:INGN), Sientra, Inc. (NASDAQ:SIEN), Boston Scientific Corporation (NYSE:BSX), Koninklijke Philips N.V. (NYSE:PHG), Irhythm Technologies Inc. (NASDAQ:IRTC), Soliton Inc. (NASDAQ:SOLY), Neuronetics Inc. (NASDAQ:STIM), Eargo Inc. (NASDAQ:EAR), electroCore, Inc. (NASDAQ:ECOR), IsoRay, Inc. (NYSEAMERICAN:ISR), ReWalk Robotics Ltd (NASDAQ:RWLK), Sensus Healthcare (NASDAQ:SRTS)